|Fighting Blindness with 3D-NET "Drug Discovery & Development of Novel Eye Therapeutics"|
Pilar Ventosa-Andrés, Nils Ohnesorge, Yolanda Fernández, Yolanda Alvarez and Breandán Kennedy
3D-NET, “Drug Discovery & Development of Novel Eye Therapeutics”, is a new European research consortium of industry and academic partners focusing efforts to enhance the discovery and development of drugs targeting ocular pathologies that lead to blindness.
|"In-vitro studies on hydroxamic acid- CT DNA binding" |
In vitro studies of five the interaction between five different derivatives of hydroxamic acids, N-phenyl 2,4dichloro phenoxybutyro, N-m-tolyl 2,4 dichlorophenoxyglutero, N-m-tolyl-4-chlorophenoxyaceto, N-m-chloro-phenyl-tertiarybutylbenzo and N-p-tolyl-iso-valero hydroxamic acids and calf thymus DNA was investigated under simulated physiological condition.
|Metabolism of Eight Model Pharmaceutical Compounds in Rat and Human HepatoPac Versus Liver Microsomes and Suspension Hepatocyte Platforms|
Julius O. Enoru, William DeMaio, Adiba Watanyar, Kenneth Draper, Amanda Moore & Okey Ukairo
This poster presents our comparative metabolite profiling analysis of eight model pharmaceutical compounds with various biotransformation reactions using a functionally stable model of primary hepatocytes [micropatterned co-cultures (MPCCs)] in parallel with the traditional liver microsomal and suspension hepatocyte systems.
|Automated Fluorescence Detection and Imaging of RNA Species in Live Cells|
Paul Held, Victor Koong, Don Weldon, Peter Banks
This poster describes the detection and quantification of RNA species in Live cells through automated imaging.
|Validation of a 3-Dimensional Human Liver Microtissue Model for Long-term Hepatotoxicity Studies|
Brad Larson1, Stewart Hunt2, Timothy Moeller3, Diana Long4, and Peter Banks1
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drug commonly used as analgesics and antipyretics, as well as for management of rheumatological disorders. They are one of the most highly prescribed drug families around the world, and consequently, along with antimicrobial agents, are the most frequent causes of druginduced liver injury (DILI) (Bjornsson et al., 2010).
|Metabolic Stability Assay Using Human Hepatocyte Co-cultures and Integrated Qualitative/Quantitative High Resolution Mass Spectrometry|
Alex Zang, Ragu Ramanathan, Cornelia Smith, Caroline Lee, Helen Shen, and Zamas Lam
Purpose: To investigate Sequential Window Acquisition of all Theoretical fragment ion spectra (SWATH™) based integrated qualitative and quantitative (qual/quant) assay for simultaneous metabolic stability and metabolite profiling assessments.
|In Vitro Species Comparison Using Long-Term Hepatocyte Co-Cultures Model and Highly Sensitive UHPLC-QTOF-MS with SWATH Analysis|
Jian Yu; Ragu Ramanathan; Cornelia Smith; Caroline Lee; Helen Shen; Zamas Lam
Purpose: To develop a reliable, quicker, and cost-saving in vitro method to accurately predict major human metabolite profile in vivo and to de-risk disproportional or unique human metabolites before a drug candidate nomination
|Metabolite Profiling Using Human Hepatocyte Co-cultures and UHPLC-QTOF-MS with Data Independent MS/MS|
Ronghua Wang, Ragu Ramanathan, Cornelia Smith, Caroline Lee, Helen Shen, and Zamas Lam
To investigate a high throughput workflow for metabolite profiling using a novel human in vitro system and advanced UHPLC-MS/MS techniques to accurately predict human metabolite profile in vivo.
|TOXICITY OF SELECTED BIOACTIVATED COMPOUNDS IN PRIMARY RAT HEPATOCYTES CULTURED IN MICROPATTERNED CO-CULTURES|
Okechukwu Ukairo, Julianne Shi, Justin Jackson, Kelly Rose, Melvin E. Andersen, and Edward L. LeCluyse
Drug Induced Liver Injury (DILI) modeled in a novel co-culture liver model. Here, we assess the bioactivation and cytotoxicity of acetaminophen (APAP) and other compounds in the 96-well rat MPCC.